Evidence map›Paper›PMID 25432328›Full record

ArticleJournal of endocrinological investigation2015

The evaluation of Nesfatin-1 levels in patients with OSAS associated with metabolic syndrome.

O Aksu, B Aydın, D K Doguç, I Ilhan, O Ozturk, A Altuntas, H Demirkan, B K Koroglu, M N Tamer

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Sleep apnea syndrome in endocrine clinics.Journal of endocrinological investigation · 2015
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

O AksuDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, School of medicine, 3200, Isparta, Turkey. droaksu@yahoo.com.
B AydınDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, School of medicine, 3200, Isparta, Turkey.
D K DoguçDepartment of Biochemistry, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.
I IlhanDepartment of Biochemistry, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.
O OzturkDepartment of Chest Disease, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.
A AltuntasDivision of Nephrology, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.
H DemirkanDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, School of medicine, 3200, Isparta, Turkey.
B K KorogluDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, School of medicine, 3200, Isparta, Turkey.
M N TamerDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, School of medicine, 3200, Isparta, Turkey.
Süleyman Demirel University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe association of obstructive sleep apnea syndrome (OSAS) and metabolic syndrome (MS) has been demonstrated in studies and in recent years; the effect of OSAS on insulin resistance independent of the level of obesity is being investigated. Nesfatin-1 is a newly defined 82 amino acid protein with a precursor molecule of NUCB2 (nucleobindin 2). Nesfatin-1 is not only essential in regulation of food ingestion but also important in regulation of some brain functions, autonomic regulation, stress, mental state, and paradoxical sleep. We aimed to evaluate the relationship between OSAS and MS and the MS dependent or independent effect of Nesfatin-1 on this relationship.

methodsPatients admitted with clinical signs of OSAS are included. Patients are divided into three groups based on Apnea-Hypopnea Index (AHI) on Polysomnography (PSG) as mild, moderate, and severe OSAS. A total of 59 patients were included the control patients. Several OSAS parameters and laboratory findings which are and are not MS dependent are compared. Nesfatin-1 levels are evaluated in all OSAS patients with and without MS.

resultsThere were significantly more males in all groups (p = 0.007). There was no significant difference between groups in terms of Nesfatin-1 levels. Nesfatin-1 levels were significantly lower in MS group compared to non-MS group (p = 0.021).

conclusionNesfatin-1 which is known to play a role in the pathophysiology of insulin resistance can be a beneficial target in developing new therapeutic targets for treatment of patients with obesity without any toxic effects in the future.

Indexed as

AdolescentAdultAgedCalcium-Binding ProteinsComorbidityDNA-Binding ProteinsFemaleHumansMaleMetabolic SyndromeMiddle AgedNerve Tissue ProteinsNucleobindinsObesitySleep Apnea, ObstructiveYoung AdultCalcium-Binding ProteinsDNA-Binding ProteinsNerve Tissue ProteinsNUCB2 protein, humanNucleobindinsMetabolic syndromeNesfatin-1Obstructive sleep apnea syndrome

Identifiers

PMID25432328
OpenAlexW2125222154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.